Sodium-dependent glucose transporters (SGLT) in human ischemic heart: A new potential pharmacological target

International Journal of Cardiology
Alessandra Di FrancoEdoardo Mannucci

Abstract

Empagliflozin is reported to reduce cardiovascular mortality and the rate of hospitalization for heart failure in type 2 diabetic patients with prior cardiovascular events. The mechanisms underlying the cardiac effects of this sodium/glucose transporter 2 (SGT2) inhibitor have not yet been clarified, though a direct action of the drug on the cardiomyocytes could be hypothesized. The aim of the present study is to assess the relative expression of SGLT2 and SGLT1, the two most relevant members of the SGLT family being potentially responsive to empagliflozin, in normal, ischemic and hypertrophic human hearts. Tissue biopsies of healthy (n=9), ischemic (n=9) and hypertrophic (n=6) human hearts were analyzed by real time quantitative RT-PCR, confocal immunofluorescence and Western blot techniques. We found no expression of SGLT2 in either normal or pathological conditions, whereas SGLT1 was expressed in normal myocardial tissue and significantly upregulated in ischemia and hypertrophy, in association with increased phosphorylation in activating domains of the intracellular second messengers AMP-activated protein kinase (AMPK), extracellular-signal regulated kinase 1 and 2 (ERK-1/2) and mammalian target of rapamycin (mTOR). These fi...Continue Reading

Citations

Jan 13, 2018·Heart Failure Reviews·Abdullah KaplanFouad A Zouein
Oct 11, 2017·Cardiovascular Research·Edoardo BerteroChristoph Maack
Jul 3, 2018·Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan·Masamichi HiroseMaki Saito
Oct 18, 2018·European Journal of Heart Failure·Steffen PabelSamuel Sossalla
Nov 27, 2018·Expert Opinion on Drug Metabolism & Toxicology·Mattia GalliNadia Aspromonte
May 14, 2019·Diabetes, Obesity & Metabolism·Jessica A Dominguez Rieg, Timo Rieg
Apr 11, 2019·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Elizabeth A HausnerXi Yang
Mar 16, 2019·Cardiovascular Research·Alvaro Garcia-RoperoJuan J Badimon
Aug 29, 2019·Current Topics in Medicinal Chemistry·Ban LiuBiao Yan
Mar 8, 2018·Molecular Medicine Reports·Liping MengHiroshi Tada
Mar 7, 2020·Frontiers in Cardiovascular Medicine·Nina Kaludercic, Fabio Di Lisa
Aug 9, 2020·Pflügers Archiv : European journal of physiology·Gergely GyimesiMatthias A Hediger
Nov 9, 2018·International Journal of Molecular Sciences·Philipp Glosse, Michael Föller
Aug 7, 2019·Cardiovascular Diabetology·Aaron Y KlugerPeter A McCullough
Jul 7, 2019·International Journal of Molecular Sciences·Álvaro García-RoperoJuan J Badimon
Jul 16, 2020·Nature Reviews. Cardiology·Martin R Cowie, Miles Fisher
Sep 22, 2020·EMBO Molecular Medicine·Mark SweeneyStuart A Cook
Oct 31, 2020·International Journal of Molecular Sciences·Florian JuszczakAnne-Emilie Declèves
Feb 4, 2021·Heart Failure Reviews·Maja NikolicVladimir Jakovljevic
Jan 9, 2021·American Journal of Physiology. Heart and Circulatory Physiology·Laura FertéChristophe Beauloye
Oct 24, 2020·Expert Review of Cardiovascular Therapy·Alvaro Garcia-RoperoJuan J Badimon
Nov 17, 2020·Drug Design, Development and Therapy·Na Li, Hong Zhou
Mar 31, 2021·Life Sciences·Mohammed Ali AzamKumaraswamy Nanthakumar
Jun 3, 2021·International Journal of Molecular Sciences·David BodeFelix Hohendanner

❮ Previous
Next ❯

Related Concepts

Related Feeds

Brain Ischemia

Brain ischemia is a condition in which there is insufficient blood flow to the brain to meet metabolic demand. Discover the latest research on brain ischemia here.

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.